Stuart Sprague to Renal Dialysis
This is a "connection" page, showing publications Stuart Sprague has written about Renal Dialysis.
Connection Strength
7.052
-
Should phosphate management be limited to the KDIGO/ KDOQI guidelines? Semin Dial. 2018 07; 31(4):377-381.
Score: 0.511
-
Long-term efficacy and safety of sucroferric oxyhydroxide in African American dialysis patients. Hemodial Int. 2018 10; 22(4):480-491.
Score: 0.510
-
Real-world effectiveness of sucroferric oxyhydroxide in patients on chronic hemodialysis: A retrospective analysis of pharmacy data?. Clin Nephrol. 2017 Aug; 88(8):59-67.
Score: 0.486
-
Diagnostic Accuracy of Bone Turnover Markers and Bone Histology in Patients With CKD Treated by Dialysis. Am J Kidney Dis. 2016 Apr; 67(4):559-66.
Score: 0.425
-
Effect of Cinacalcet and Vitamin D Analogs on Fibroblast Growth Factor-23 during the Treatment of Secondary Hyperparathyroidism. Clin J Am Soc Nephrol. 2015 Jun 05; 10(6):1021-30.
Score: 0.414
-
Painful skin ulcers in a hemodialysis patient. Clin J Am Soc Nephrol. 2014 Jan; 9(1):166-73.
Score: 0.375
-
Is bone mineral density measurement of any value in a dialysis patient? Semin Dial. 2011 Jul-Aug; 24(4):433-4.
Score: 0.320
-
Lanthanum carbonate vs. sevelamer hydrochloride for the reduction of serum phosphorus in hemodialysis patients: a crossover study. Clin Nephrol. 2009 Oct; 72(4):252-8.
Score: 0.282
-
Simultaneous control of PTH and CaxP Is sustained over three years of treatment with cinacalcet HCl. Clin J Am Soc Nephrol. 2009 Sep; 4(9):1465-76.
Score: 0.280
-
When is Vitamin D contraindicated in dialysis patients? Semin Dial. 2009 May-Jun; 22(3):249-51.
Score: 0.274
-
Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trial. Clin J Am Soc Nephrol. 2009 Jan; 4(1):178-85.
Score: 0.267
-
Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int. 2007 Oct; 72(7):895; author reply 895-6.
Score: 0.246
-
Serum Phosphorus Management with Sucroferric Oxyhydroxide as a First-Line Phosphate Binder within the First Year of Hemodialysis. Am J Nephrol. 2024; 55(2):127-135.
Score: 0.189
-
Managing Phosphate Burden in Patients Receiving Dialysis: Beyond Phosphate Binders and Diet. Kidney360. 2023 11 01; 4(11):1650-1656.
Score: 0.187
-
Dialysis-related amyloidosis. Minerva Urol Nefrol. 2003 Jun; 55(2):121-9.
Score: 0.182
-
Suppression of parathyroid hormone secretion in hemodialysis patients: comparison of paricalcitol with calcitriol. Am J Kidney Dis. 2001 Nov; 38(5 Suppl 5):S51-6.
Score: 0.163
-
A safety evaluation of sucroferric oxyhydroxide for the treatment of hyperphosphatemia. Expert Opin Drug Saf. 2021 Dec; 20(12):1463-1472.
Score: 0.163
-
Effects of sucroferric oxyhydroxide and sevelamer carbonate on chronic kidney disease-mineral bone disorder parameters in dialysis patients. Nephrol Dial Transplant. 2019 07 01; 34(7):1163-1170.
Score: 0.139
-
Sucroferric oxyhydroxide for the treatment of hyperphosphatemia. Expert Opin Pharmacother. 2018 Jul; 19(10):1137-1148.
Score: 0.130
-
Iron-related parameters in dialysis patients treated with sucroferric oxyhydroxide. Nephrol Dial Transplant. 2017 Aug 01; 32(8):1330-1338.
Score: 0.121
-
Pharmacodynamic Effects of Sucroferric Oxyhydroxide and Sevelamer Carbonate on Vitamin D Receptor Agonist Bioactivity in Dialysis Patients. Am J Nephrol. 2016; 44(2):104-12.
Score: 0.113
-
Advanced glycation of beta 2-microglobulin in the pathogenesis of bone lesions in dialysis-associated amyloidosis. Nephrol Dial Transplant. 1996; 11 Suppl 3:86-90.
Score: 0.109
-
A Randomized Trial of Cinacalcet versus Vitamin D Analogs as Monotherapy in Secondary Hyperparathyroidism (PARADIGM). Clin J Am Soc Nephrol. 2015 Jun 05; 10(6):1031-40.
Score: 0.104
-
Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients. Nephrol Dial Transplant. 2015 Jun; 30(6):1037-46.
Score: 0.102
-
Maintenance of bone mass in patients receiving dialytic therapy. Am J Kidney Dis. 1993 Aug; 22(2):300-7.
Score: 0.092
-
Serum amyloid P component: a predictor of clinical beta 2-microglobulin amyloidosis. Am J Kidney Dis. 1992 May; 19(5):427-32.
Score: 0.084
-
Association of serum alkaline phosphatase and bone mineral density in maintenance hemodialysis patients. Hemodial Int. 2010 Apr; 14(2):182-92.
Score: 0.073
-
Control of secondary hyperparathyroidism by vitamin D receptor agonists in chronic kidney disease. Clin J Am Soc Nephrol. 2010 Mar; 5(3):512-8.
Score: 0.072
-
Relationship of aluminum to neurocognitive dysfunction in chronic dialysis patients. Arch Intern Med. 1988 Oct; 148(10):2169-72.
Score: 0.066
-
Higher strength lanthanum carbonate provides serum phosphorus control with a low tablet burden and is preferred by patients and physicians: a multicenter study. Clin J Am Soc Nephrol. 2008 Sep; 3(5):1437-45.
Score: 0.065
-
Beta2-microglobulin stimulates osteoclast formation. Kidney Int. 2008 Jun; 73(11):1275-81.
Score: 0.064
-
Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis. Am J Nephrol. 2008; 28(1):97-106.
Score: 0.061
-
Encephalopathy in chronic renal failure responsive to deferoxamine therapy. Another manifestation of aluminum neurotoxicity. Arch Intern Med. 1986 Oct; 146(10):2063-4.
Score: 0.057
-
Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings. Nephrol Dial Transplant. 2004 May; 19(5):1174-81.
Score: 0.048
-
Sucroferric oxyhydroxide for hyperphosphatemia: a review of real-world evidence. J Nephrol. 2022 04; 35(3):875-888.
Score: 0.042
-
Characteristics of Patients Who Achieve Serum Phosphorus Control on Sucroferric Oxyhydroxide or Sevelamer Carbonate: A post hoc Analysis of a Phase 3 Study. Nephron. 2020; 144(9):428-439.
Score: 0.037
-
Effect of a low calcium dialysate on parathyroid hormone secretion in diabetic patients on maintenance hemodialysis. J Bone Miner Res. 2000 May; 15(5):927-35.
Score: 0.037
-
Is beta 2-microglobulin a mediator of bone disease? Kidney Int. 1995 Jan; 47(1):1-6.
Score: 0.025
-
Hypocalcemia in end-stage renal disease: a consequence of spontaneous parathyroid gland infarction. Am J Kidney Dis. 1994 Sep; 24(3):519-22.
Score: 0.025
-
Safety and efficacy of long-term treatment of secondary hyperparathyroidism by low-dose intravenous calcitriol. Am J Kidney Dis. 1992 Jun; 19(6):532-9.
Score: 0.021
-
Aluminum neurotoxicity: a reevaluation. Clin Neuropharmacol. 1991 Apr; 14(2):179-85.
Score: 0.020
-
KDOQI US commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD-Mineral and Bone Disorder (CKD-MBD). Am J Kidney Dis. 2010 May; 55(5):773-99.
Score: 0.018
-
Association of relatively low serum parathyroid hormone with malnutrition-inflammation complex and survival in maintenance hemodialysis patients. J Ren Nutr. 2010 Jul; 20(4):243-54.
Score: 0.018
-
Assessment of the stability of an immunoadsorbent for the extracorporeal removal of Beta-2-microglobulin from blood. Blood Purif. 2005; 23(4):287-97.
Score: 0.013
-
The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. Kidney Int. 2003 Jan; 63(1):248-54.
Score: 0.011
-
Factors affecting tissue aluminum concentration. J Dial. 1978; 2(5-6):471-81.
Score: 0.008
-
Determinants of tissue aluminum concentration. Am J Kidney Dis. 1981 Nov; 1(3):141-5.
Score: 0.003